FOXP3 and neoplasm: Combination therapy promoted a significant and sustained reduction of CD4+FoxP3+ Tregs in the EMT6 TME (Fig. 3d, e), without significantly affecting FoxP3− CD4+ tumor-infiltrating lymphocytes (TILs) (Supplementary Fig. 4).